Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
and TEL-PDGFβR
59(4):1440-54
is an inhibitors of ERK protein kinase
LC3-mHTT-IN-AN1 interacts with both LC3 and mHTT
is a drug for the treatment of multi-drug-resistant tuberculosis
Vemurafenib - CAS# 918504-65-1 0069 and TEL-PDGFβRVemurafenib, CAS No. 918504 65 1, also known as PLX4032, RG7204 or RO5185426, is an orally bioavailable, ATP competitive, small molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib received FDA approval for the treatment of late stage melanoma on August 17, 2011. Vemurafenib selectively binds to the ATP binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over